FendX Technologies (CSE:FNDX) Plans to Settle Debts with Share Issuance

Vancouver, British Columbia — November 24, 2025 — Leads & Copy —

FendX Technologies Inc. plans to settle outstanding debts totaling approximately $25,560 with two consultants by issuing 34,540 common shares at a deemed price of $0.74 per share. The company’s stock is traded as CSE: FNDX, OTCQB: FDXTF and FSE: E8D0.

The debts are owed to two arms-length consultants for services previously performed. FendX Technologies Inc. originally announced the consulting agreements with each consultant on June 11, 2025, and July 9, 2025. The original agreements set out the debt settlement pricing terms. Per amending agreements with each consultant, the debt settlement price per share was amended to the greater of:

  • The Company’s market price on the date that is at least 5 business days prior to the closing;
  • The Company’s 5 day VWAP calculated for the five trading day period that is at least 5 business days prior to the closing; or
  • Such higher price as may be agreed to between the parties.

The Shares proposed to be issued pursuant to the debt settlements will be subject to a statutory four-month and one-day hold period in accordance with applicable securities laws.

Closing of the debt settlements is contingent upon customary conditions precedent, including receipt of all necessary regulatory approvals, including the approval of the Canadian Securities Exchange (CSE).

The company is developing solutions to help reduce the spread of harmful pathogens in everyday environments. FendX is focused on building a robust intellectual property portfolio in the surface protection space. The Company is committed to identifying and advancing new technologies and materials that enhance hygiene and safety across healthcare, consumer, and commercial settings.

Carolyn Myers, Chief Executive Officer and Director, is acting on behalf of the company.

Investor Relations can be contacted at 1-800-344-9868 or investor@fendxtech.com.

Neither the Canadian Securities Exchange nor the Market Regulator accepts responsibility for the adequacy or accuracy of this release.

Source: FendX Technologies Inc.

Source: FendX Technologies Inc.

×

Welcome!

BiotechReporter.news is a Leads & Copy Publication

Leads & Copy is a Media “news tip” source, providing Industry Reporters story Leads, written as Publishable CP-style Copy.

By Subscribing you will receive Daily Biotech Story Leads via email 10:30 am Mon-Fri.